Cargando…

Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer

The present study was undertaken to detect circulating IgG antibodies to peptide antigens derived from baculoviral IAP repeat-containing protein 5 isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) in cervical cancer. A total of 107 female patients with cervical cancer of stages I and II, and 13...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yangchun, Jin, Yonglong, Liu, Linlin, Zhang, Xuan, Chen, Yubing, Wei, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382516/
https://www.ncbi.nlm.nih.gov/pubmed/25853035
http://dx.doi.org/10.1016/j.fob.2015.03.007
_version_ 1782364594802524160
author Xu, Yangchun
Jin, Yonglong
Liu, Linlin
Zhang, Xuan
Chen, Yubing
Wei, Jun
author_facet Xu, Yangchun
Jin, Yonglong
Liu, Linlin
Zhang, Xuan
Chen, Yubing
Wei, Jun
author_sort Xu, Yangchun
collection PubMed
description The present study was undertaken to detect circulating IgG antibodies to peptide antigens derived from baculoviral IAP repeat-containing protein 5 isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) in cervical cancer. A total of 107 female patients with cervical cancer of stages I and II, and 130 healthy female subjects were recruited for analysis of circulating IgG antibodies to BIRC5 and MYC. Student’s t-test showed significant differences in circulating levels of anti-BIRC5 IgG (t = −4.27, df = 235, P < 0.0001) and anti-MYC IgG (t = 3.51, df = 232, P = 0.0005) between the patient group and the control group. Receiver operating characteristic (ROC) analysis showed an area under the ROC curve (AUC) of 0.67 with sensitivity of 23.4% against specificity of 90% for the anti-BIRC5 IgG assay and an AUC of 0.66 with sensitivity of 9.4% against specificity of 90.6% for the anti-MYC IgG assay. Analysis of quality control samples gave an inter-assay deviation of 8.9% in the anti-BIRC5 IgG assay and 9.0% in the anti-MYC IgG assay. This work suggests that anti-BIRC5 IgG could serve as a biomarker for early diagnosis of cervical cancer although a panel of such tumor-associated antigens is needed to develop a highly sensitive test.
format Online
Article
Text
id pubmed-4382516
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-43825162015-04-07 Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer Xu, Yangchun Jin, Yonglong Liu, Linlin Zhang, Xuan Chen, Yubing Wei, Jun FEBS Open Bio Article The present study was undertaken to detect circulating IgG antibodies to peptide antigens derived from baculoviral IAP repeat-containing protein 5 isoform 2 (BIRC5) and myc proto-oncogene protein (MYC) in cervical cancer. A total of 107 female patients with cervical cancer of stages I and II, and 130 healthy female subjects were recruited for analysis of circulating IgG antibodies to BIRC5 and MYC. Student’s t-test showed significant differences in circulating levels of anti-BIRC5 IgG (t = −4.27, df = 235, P < 0.0001) and anti-MYC IgG (t = 3.51, df = 232, P = 0.0005) between the patient group and the control group. Receiver operating characteristic (ROC) analysis showed an area under the ROC curve (AUC) of 0.67 with sensitivity of 23.4% against specificity of 90% for the anti-BIRC5 IgG assay and an AUC of 0.66 with sensitivity of 9.4% against specificity of 90.6% for the anti-MYC IgG assay. Analysis of quality control samples gave an inter-assay deviation of 8.9% in the anti-BIRC5 IgG assay and 9.0% in the anti-MYC IgG assay. This work suggests that anti-BIRC5 IgG could serve as a biomarker for early diagnosis of cervical cancer although a panel of such tumor-associated antigens is needed to develop a highly sensitive test. Elsevier 2015-03-17 /pmc/articles/PMC4382516/ /pubmed/25853035 http://dx.doi.org/10.1016/j.fob.2015.03.007 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Xu, Yangchun
Jin, Yonglong
Liu, Linlin
Zhang, Xuan
Chen, Yubing
Wei, Jun
Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer
title Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer
title_full Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer
title_fullStr Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer
title_full_unstemmed Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer
title_short Study of circulating IgG antibodies to peptide antigens derived from BIRC5 and MYC in cervical cancer
title_sort study of circulating igg antibodies to peptide antigens derived from birc5 and myc in cervical cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382516/
https://www.ncbi.nlm.nih.gov/pubmed/25853035
http://dx.doi.org/10.1016/j.fob.2015.03.007
work_keys_str_mv AT xuyangchun studyofcirculatingiggantibodiestopeptideantigensderivedfrombirc5andmycincervicalcancer
AT jinyonglong studyofcirculatingiggantibodiestopeptideantigensderivedfrombirc5andmycincervicalcancer
AT liulinlin studyofcirculatingiggantibodiestopeptideantigensderivedfrombirc5andmycincervicalcancer
AT zhangxuan studyofcirculatingiggantibodiestopeptideantigensderivedfrombirc5andmycincervicalcancer
AT chenyubing studyofcirculatingiggantibodiestopeptideantigensderivedfrombirc5andmycincervicalcancer
AT weijun studyofcirculatingiggantibodiestopeptideantigensderivedfrombirc5andmycincervicalcancer